Skip to Content

Morphic Holding Inc MORF

Morningstar Rating
$27.51 −0.36 (1.29%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MORF is trading at a 68% discount.
Price
$28.23
Fair Value
$26.49
Uncertainty
Extreme
1-Star Price
$862.99
5-Star Price
$84.81
Economic Moat
Jmtz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MORF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$27.87
Day Range
$27.2428.13
52-Week Range
$19.3563.08
Bid/Ask
$27.52 / $27.56
Market Cap
$1.38 Bil
Volume/Avg
369,158 / 468,102

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2,237.59
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
121

Comparables

Valuation

Metric
MORF
CBAY
PLRX
Price/Earnings (Normalized)
Price/Book Value
1.9612.651.63
Price/Sales
2,237.59111.01477.92
Price/Cash Flow
Price/Earnings
MORF
CBAY
PLRX

Financial Strength

Metric
MORF
CBAY
PLRX
Quick Ratio
28.4310.7017.43
Current Ratio
28.9410.9617.72
Interest Coverage
−5.27−145.34
Quick Ratio
MORF
CBAY
PLRX

Profitability

Metric
MORF
CBAY
PLRX
Return on Assets (Normalized)
−19.79%−30.06%−22.68%
Return on Equity (Normalized)
−20.47%−51.97%−24.50%
Return on Invested Capital (Normalized)
−23.98%−30.87%−28.46%
Return on Assets
MORF
CBAY
PLRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJdnyxswdxXzgph$553.3 Bil
VRTX
Vertex Pharmaceuticals IncKmtjygqCtxkszh$101.6 Bil
REGN
Regeneron Pharmaceuticals IncMjcyrfmhgTnkmsn$98.9 Bil
MRNA
Moderna IncBslwdslvcRdd$39.7 Bil
ARGX
argenx SE ADRNfgmhtcmZbxp$21.5 Bil
BNTX
BioNTech SE ADRNxqlsrrSzjr$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncVcmqxxrzSqjhgs$18.4 Bil
BMRN
Biomarin Pharmaceutical IncTmgbgtftMfbfkjx$17.1 Bil
RPRX
Royalty Pharma PLC Class ATvkspjfljFbdyc$12.3 Bil
INCY
Incyte CorpLpkqlvdhYcqgqn$11.8 Bil

Sponsor Center